Clinical Trial Update: A Study of the Safety, Tolerability, and Pharmacokinetics of Dolutegravir in Neonates Exposed to HIV-1 [Phase 1]

View source ↗

Summary

This Phase 1 trial assessed the safety, tolerability, and pharmacokinetics of dolutegravir in neonates exposed to HIV-1, and the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Tivicay (dolutegravir)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: HIV | Phase 1 | Status: COMPLETED